Olonex 5 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Olopatadine hydrochloride |
| Company | Beacon pharmaceuticals plc |
Title
Olopatadine Medicine Product
Categories
- Allergic Conjunctivitis Treatment
- Allergic Rhinitis Relief
- Allergy Medication
Description
Olopatadine is an antihistamine indicated for the treatment of signs and symptoms of allergic conjunctivitis, vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis, giant papillary conjunctivitis, and seasonal allergic rhinitis.
Color Options
- Clear
Formulations
- Eye Drops
- Nasal Spray
- Tablet
Dosage Strengths
- 0.1%
- 0.2%
- 0.7%
- 5mg
Dosage Instructions
- One drop in each affected eye two times per day at an interval of 6 to 8 hours for 0.1% eye drops
- One drop in the affected eye once a day for 0.2% eye drops
- One drop in each affected eye once a day for 0.7% eye drops
- Two sprays per nostril twice daily for adults and adolescents 12 years of age and older for Nasal Spray
- One spray per nostril twice daily for children 6 to 11 years of age for Nasal Spray
- Take 1 tablet (5 mg) at a time, twice daily, in the morning and before going to bed for adults and children 7 years old or over
Administration Guide
- Instructions for using the Nasal Spray
- Instructions for cleaning the Nasal Spray
Pharmacology
Olopatadine works by blocking histamine action and reducing allergy symptoms. It stabilizes mast cells, inhibits histamine release, and acts as an antagonist at histamine H1 receptors with high selectivity.
Pharmacokinetics
- Absorption: Olopatadine is absorbed with peak plasma concentrations observed between 30 minutes and 1 hour after intranasal administration.
- Distribution: The protein binding of olopatadine is moderate at approximately 55% in human serum.
- Metabolism: Olopatadine is not extensively metabolized, with at least six minor metabolites circulating in human plasma.
- Elimination: The plasma elimination half-life of olopatadine is 8 to 12 hours, mainly eliminated through urinary excretion.
Interaction
No formal drug-drug interaction studies have been conducted. Olopatadine is eliminated predominantly by renal excretion, and interactions involving P450 inhibition are not expected.
Contraindications
Contraindicated in persons with known hypersensitivity to any component of the product. Not recommended for use in individuals allergic to olopatadine.
Side Effects
- Common:
- Headaches
- Rare:
- Asthenia
- Blurred Vision
- Burning or Stinging
- Cold Syndrome
- Dry Eye
- Foreign Body Sensation
- Hyperemia
- Hypersensitivity
- Keratitis
- Lid Edema
- Nausea
- Pharyngitis
- Pruritus
- Rhinitis
- Sinusitis
- Taste Perversion
Pregnancy & Lactation
- Teratogenicity: Not teratogenic in rats and rabbits
- Use in Pregnant Women: Should be used only if potential benefit justifies potential risk to the fetus
- Use in Nursing Mothers: Caution should be exercised when administered to a nursing mother
Precautions
Patients should be advised not to wear a contact lens if their eye is red. The treatment should be discontinued in the presence of an allergic reaction. Dosage should be used as prescribed by a doctor, and patients should avoid taking more than the recommended dose.
Use in Special Populations
- Geriatric Use: No overall differences in safety or effectiveness observed
Overdose Effects
No information on overdose, excessive use can have serious consequences, seek medical attention if suspected
Therapeutic Class
Ophthalmic Non-Steroid Drugs
Storage Conditions
Store at room temperature, protect from light, and use contents within one month after first opening